
Vilya is a computational biotechnology company focused on creating a new class of medicines by precisely targeting disease biology. Their platform leverages advanced computational approaches and explores uncharted chemical space to design novel molecular structures, including macrocycles, that possess enhanced drug-like properties. Vilya aims to revolutionize medicine creation by using computing to surpass traditional high-throughput screening methods and ultimately cure diseases. The company was co-founded by scientists from the Institute of Protein Design (IPD), led by David Baker, Ph.D., and ARCH Venture Partners. Recent news highlights include Dr. David Baker's Nobel Prize in Chemistry and a $71 million Series A financing expansion to advance their computational drug design.

Vilya is a computational biotechnology company focused on creating a new class of medicines by precisely targeting disease biology. Their platform leverages advanced computational approaches and explores uncharted chemical space to design novel molecular structures, including macrocycles, that possess enhanced drug-like properties. Vilya aims to revolutionize medicine creation by using computing to surpass traditional high-throughput screening methods and ultimately cure diseases. The company was co-founded by scientists from the Institute of Protein Design (IPD), led by David Baker, Ph.D., and ARCH Venture Partners. Recent news highlights include Dr. David Baker's Nobel Prize in Chemistry and a $71 million Series A financing expansion to advance their computational drug design.
Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology. We believe computational approaches are an integral, if not foundational, component of drug discovery and development.
We are harnessing the power of our platform to go after previously impossible targets in an array of indications. Vilya’s ultimate goal is to solve some of the most challenging unmet medical needs that exist today.
Our Vision: Harness a revolution in technology and biology to better human health.
Our Mission: Build an independent, leading biotech company founded on intelligent drug design to cure the incurable.
We are seeking a Scientist, Macrocycle Design to apply state-of-the-art de novo design methodologies to computationally discover, develop, and evaluate therapeutic macrocycles. As a member of the design team in Seattle WA, you will leverage your knowledge of cutting edge methods in molecular design to augment Vilya’s existing design platform.
Vilya is a team-first organization, and we believe onsite work is essential to how we collaborate, move quickly, and build a strong culture. This is an onsite position in our Seattle office. Join us and help make a difference for patients!
Responsibilities
Preferred Qualifications
Vilya Benefits
Salary Range : $120,000-$160,000/year